Juan  Vera net worth and biography

Juan Vera Biography and Net Worth

Director of AlloVir
Dr. Vera is an Associate Professor at Baylor College of Medicine.
Dr. Juan Vera has more than 15 years of experience performing research in the field of adoptive T cell therapy and has made several contributions in the field, specifically in the areas of genetic engineering T cells manufacture process optimization. He has extensive expertise developing and streamlining therapeutic candidates from the research bench to the cGMP facility while ensuring robust production and scalability.

In collaboration with Wilson Wolf Manufacturing, Dr. Vera has been instrumental in the design and testing of the G-Rex® cell culture platform and pioneered its use for the large-scale production of T cells. He is a Co-Investigator on a number of clinical trials for T cell therapy in both infectious disease and cancer. His recent focus is on developing strategies to enhance the T cell function by protecting tumor-targeted T cells from the immunosuppressive effects of the tumor microenvironment in order to enhance in vivo persistence and function.

Dr. Vera is senior or co-author on more than 30 publications and a named inventor on 13 published patents. He is based at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston where he holds the title of Associate Professor in the Dept. of Medicine. Dr. Vera received his Medical Degree from the University El Bosque in Bogota, Colombia and completed his postgraduate training in theCenter for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital.

What is Juan Vera's net worth?

The estimated net worth of Juan Vera is at least $2.00 million as of March 16th, 2021. Dr. Vera owns 2,564,487 shares of AlloVir stock worth more than $2,000,300 as of April 25th. This net worth approximation does not reflect any other investments that Dr. Vera may own. Learn More about Juan Vera's net worth.

How do I contact Juan Vera?

The corporate mailing address for Dr. Vera and other AlloVir executives is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. AlloVir can also be reached via phone at 617-433-2605 and via email at [email protected]. Learn More on Juan Vera's contact information.

Has Juan Vera been buying or selling shares of AlloVir?

Juan Vera has not been actively trading shares of AlloVir during the last quarter. Most recently, Juan Vera sold 15,988 shares of the business's stock in a transaction on Wednesday, March 3rd. The shares were sold at an average price of $38.32, for a transaction totalling $612,660.16. Following the completion of the sale, the director now directly owns 2,392,194 shares of the company's stock, valued at $91,668,874.08. Learn More on Juan Vera's trading history.

Who are AlloVir's active insiders?

AlloVir's insider roster includes Ercem Atillasoy (Insider), Jeffrey Bornstein (Director), Brett Hagen (CAO), David Hallal (Director), Morana Jovan-Embiricos (Director), Ann Leen (Insider), Agustin Melian (Insider), Jeroen Van Beek (Insider), Juan Vera (Director), and John Wilson (Director). Learn More on AlloVir's active insiders.

Are insiders buying or selling shares of AlloVir?

In the last year, AlloVir insiders bought shares 1 times. They purchased a total of 2,930,870 shares worth more than $10,990,762.50. In the last year, insiders at the sold shares 44 times. They sold a total of 195,900 shares worth more than $287,187.73. The most recent insider tranaction occured on April, 22nd when CAO Brett R Hagen sold 480 shares worth more than $360.00. Insiders at AlloVir own 40.0% of the company. Learn More about insider trades at AlloVir.

Information on this page was last updated on 4/22/2024.

Juan Vera Insider Trading History at AlloVir

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/3/2021Sell15,988$38.32$612,660.162,392,194View SEC Filing Icon  
3/1/2021Sell32,854$38.59$1,267,835.862,392,194View SEC Filing Icon  
2/22/2021Sell14,321$42.57$609,644.972,426,935View SEC Filing Icon  
2/18/2021Sell8,942$40.75$364,386.502,447,910View SEC Filing Icon  
2/16/2021Sell10,400$41.86$435,344.002,457,536View SEC Filing Icon  
See Full Table

Juan Vera Buying and Selling Activity at AlloVir

This chart shows Juan Vera's buying and selling at AlloVir by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AlloVir Company Overview

AlloVir logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.78
Low: $0.77
High: $0.79

50 Day Range

MA: $0.74
Low: $0.69
High: $0.80

2 Week Range

Now: $0.78
Low: $0.62
High: $6.12

Volume

147,469 shs

Average Volume

1,174,591 shs

Market Capitalization

$89.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86